Benitec Biopharma (BNTC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 82.9% versus a loss of 34.8%. Over five years, SRZN leads with a -73.5% price change compared with -85.3% for BNTC. Benitec Biopharma is the larger company by market cap ($313.6 million vs $295.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | SRZN |
|---|---|---|
| Share price | $8.99 | $25.15 |
| Market cap | $313.60M | $295.54M |
| 1-day change | -0.11% | -4.65% |
| YTD return | -33.26% | +11.26% |
| 1-year return | -34.76% | +82.87% |
| 5-year return | -85.27% | -73.48% |
| EPS (TTM) | $-0.98 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $37.83 |
| 52-week low | $8.52 | $11.39 |
| Distance from 52-week high | -46.36% | -33.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +170.63% | +92.48% |
| Average volume | 150.34K | 471.01K |
| Shares outstanding | 34.88M | 11.75M |
| Employees | 24 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed BNTC by 117.6 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
BNTC vs SRZN FAQ
Which is bigger, Benitec Biopharma or Surrozen?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $313.60M compared with $295.54M for Surrozen (SRZN).
Which stock has performed better over the past year, BNTC or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.